Young Sang Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Young Sang Kim has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Hayyoung Lee
Postech Biotech Center, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea
32 shared publications - Jie-Oh Lee
Department of Life Sciences, POSTECH Biotech Center, Pohang University of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang-si 37673, Republic of Korea
28 shared publications - Van Anh Do-Thi
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea
26 shared publications - Sang Min Park
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea
25 shared publications - Geunyoung Cho
Institute of Membrane Proteins, POSTECH, Pohang, Republic of South Korea
23 shared publications - Hye Jin Jeong
Institute of Membrane Proteins, POSTECH, Pohang, Republic of South Korea
23 shared publications
Latest Publications
- Open Access
- 2 January 2025
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 29 (1) , 46-56
The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells
Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas. The tumor cells expressing sIFNγ and mbIFNγ/Fas showed slower growth rates compared to the mock-transfected cells. Furthermore, the tumorigenicity of the CT26 cells expressing mbIFNγ/Fas was significantly lower than that of cells expressing sIFNγ or the mock control. Remarkably, about 85% of the mice injected with the mbIFNγ/Fas-expressing tumors remained tumor-free for over two months. Mice that rejected mbIFNγ/Fas-expressing tumors developed systemic anti-tumor immunity against CT26 cells, which was characterized by enhanced levels of CD4+ and CD8+ T cells, as well as natural killer (NK) cells. Interestingly, splenocytes activated with the mbIFNγ/Fas-expressing tumors exhibited higher cytotoxicity than those activated with tumor cells expressing sIFNγ. These findings suggest that expressing the mbIFNγ/Fas chimera in tumor cells could be a promising strategy for developing whole tumor cell vaccines or gene therapies for cancer immunotherapy.
- 2 January 2025
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 29 (1) , 46-56
Open AccessThe anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells
Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas. The tumor cells expressing sIFNγ and mbIFNγ/Fas showed slower growth rates compared to the mock-transfected cells. Furthermore, the tumorigenicity of the CT26 cells expressing mbIFNγ/Fas was significantly lower than that of cells expressing sIFNγ or the mock control. Remarkably, about 85% of the mice injected with the mbIFNγ/Fas-expressing tumors remained tumor-free for over two months. Mice that rejected mbIFNγ/Fas-expressing tumors developed systemic anti-tumor immunity against CT26 cells, which was characterized by enhanced levels of CD4+ and CD8+ T cells, as well as natural killer (NK) cells. Interestingly, splenocytes activated with the mbIFNγ/Fas-expressing tumors exhibited higher cytotoxicity than those activated with tumor cells expressing sIFNγ. These findings suggest that expressing the mbIFNγ/Fas chimera in tumor cells could be a promising strategy for developing whole tumor cell vaccines or gene therapies for cancer immunotherapy.
- Open Access
- 30 December 2024
- Published by Elsevier in Molecules and Cells
- Vol. 48 (2) , 100175
Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model
- 30 December 2024
- Published by Elsevier in Molecules and Cells
- Vol. 48 (2) , 100175
Open AccessTumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Gating strategy to analyze the chemotactic migration of immune cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Gating strategy to analyze the chemotactic migration of immune cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
IL-9 promotes M1 polarization of macrophages in vitro
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
IL-9 promotes M1 polarization of macrophages in vitro
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Clodronate-encapsulated liposomes show cytotoxicity to BMDMs but not to B16F10 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Bodyweight change of the tumor-implanted mice in Figure 6
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Bodyweight change of the tumor-implanted mice in Figure 6
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Treatment with IL-9 induces STAT1 and STAT3 phosphorylation in RAW 264.7 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Treatment with IL-9 induces STAT1 and STAT3 phosphorylation in RAW 264.7 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Expression of IL-9R on the surface of B16F10 and 4T1 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Expression of IL-9R on the surface of B16F10 and 4T1 cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Expression of IL-9R on the surface of B16F10 and 4T1 cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from IL9 Polarizes Macrophages to M1 and Induces the Infiltration of Antitumor Immune Cells via MIP-1 and CXCR3 Chemokines
Expression of IL-9R on the surface of B16F10 and 4T1 cells